Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018) - MarketsandMarkets

Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018)

Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018) - MarketsandMarkets
Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018)
Published Sep 25, 2013
327 pages — Published Sep 25, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:



A biomarker is an identifiable and measurable characteristic, which identifies the severity and/or occurrence of a specific disease. It has major applications in the discovery and development of novel therapeutic drugs. The global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. It is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.

Advancements in discovery technologies, high demand from the indications of various diseases, increasing partnerships and collaborations to boost biomarker research activities, increase in government and private sector investments and funds for biomarker discovery, FDA support for biomarker development, and increasing utility of biomarkers in patient stratification and drug development process are the major drivers slated to propel the growth of this market. However, a few pivotal factors such as the high capital investment and low benefit-cost ratio, cumbersome biomarker validation procedure, and difficulty in sample collection and its storage are expected to hamper the growth of this market.

The global market has been segmented into discovery technologies, services, applications, and disease indications. The biomarker discovery technology market has been further segmented into omics technology, imaging technology, and bioinformatics. The omics technology segment accounts for the largest share in this market, primarily due to the increase in adoption of proteomics and genomics technologies across the globe.

In addition, the biomarker services (sample preparation, assay development, and biomarker validation and testing) and applications (drug discovery and formulation, and development of molecular diagnostics and personalized medicine) market have also been illustrated in the report. Drug discovery and development segment holds the largest share of biomarker applications market. This is attributed to the potential of biomarkers to reduce the time span of clinical trials, which ultimately decreases the overall cost of the entire drug discovery and development process.

On the basis of type of disease, the global biomarkers market is further classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis). Oncology biomarkers market accounts for the lion's share of the biomarker disease indication market and further this market is forecast to grow at the highest growth rate in the next five years. Increasing need for the early diagnosis of tumor cells is the major factor stimulating the growth of oncology market. Oncology biomarkers enhance the screening and early detection of cancer as well as facilitate the high-speed, non-invasive cancer diagnosis procedure.

The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.)

Scope of the Report

This research report categorizes the global biomarkers market on the basis of discovery technology, services, applications, and disease indications. These markets are broken down into segments and sub-segments, providing value analysis for 2011, 2012, and 2013 as well as forecast up to 2018. Each market is comprehensively analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World), to provide in-depth information on the global scenario.

By Discovery Technologies
&

  
Source:
Document ID
BT 2120
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
1.4.1 MARKET SIZE
1.4.2 KEY DATA POINTS FROM SECONDARY SOURCES
1.4.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1 DEFINITION OF BIOMARKERS
3.2 BIOMARKERS & ITS TYPES
3.3 BIOMARKERS MARKET
3.3.1 MARKET SEGMENTATION
3.3.2 CHALLENGES & OPPORTUNITIES
3.3.2.1 Challenges
3.3.2.1.1 Variability
3.3.2.1.2 Ethical considerations & acceptability
3.3.2.2 Opportunities
3.3.2.2.1 Personalized medicine
3.3.2.2.2 Companion diagnostics
3.3.3 DRIVERS & RESTRAINTS
3.3.3.1 Drivers
3.3.3.1.1 High demand boosts the growth of the biomarker market globally
3.3.3.1.2 Strategic collaborations lead to increasing applications in the market
3.3.3.1.3 Technological advances contribute to growth
3.3.3.1.4 The rising prevalence of the disease forms
3.3.3.1.5 FDA support for biomarker development
3.3.3.2 Restraints
3.3.3.2.1 Low capital investment & cost-benefit hinders growth of biomarkers
3.3.3.2.2 Biomarkers not a profitable market for small organizations
3.3.3.2.3 Sample collection & storage
3.3.3.2.4 Limited biomarker validation
3.3.3.2.5 Need for new R&D models with greater precision & flexibility

4 GLOBAL BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES
4.1 INTRODUCTION
4.2 IMAGING TECHNOLOGIES FOR BIOMARKERS DISCOVERY
4.2.1 POSITRON EMISSION TOMOGRAPHY (PET)
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY(SPECT)
4.2.3 ULTRASOUND
4.2.4 MAGNETIC RESONANCE IMAGING (MRI)
4.2.5 COMPUTED TOMOGRAPHY (CT)
4.3 OMICS TECHNOLOGIES FOR BIOMARKERS DISCOVERY
4.3.1 PROTEOMICS
4.3.1.1 Mass spectrometry
4.3.1.1.1 MALDI mass spectrometry
4.3.1.1.2 Imaging mass spectrometry
4.3.1.2 2D Gel Electrophoresis
4.3.1.3 Protein microarray technology
4.3.1.4 Antibody array technology
4.3.1.5 Peptide array technology
4.3.2 GENOMICS
4.3.2.1 Whole genome sequencing
4.3.2.2 Genotyping
4.3.2.3 Epigenetics
4.3.3 TRANSCRIPTOMICS
4.3.3.1 Microarrays
4.3.3.2 Gene expression profiling
4.3.4 METABOLOMICS
4.3.4.1 Capillary electrophoresis
4.3.4.2 Mass spectrometry based kits
4.3.4.3 Nuclear Magnetic Resonance(NMR)
4.4 BIOINFORMATICS
4.4.1 CLUSTER ANALYSIS
4.4.2 STATISTICAL ANALYSIS
4.4.3 CELL SIGNAL PATHWAYS
4.4.4 COMPUTER AIDED DESIGN
4.4.5 DATA MINING
4.4.6 PROTEIN INTERACTION MAPS

5 SERVICES MARKET OF BIOMARKERS
5.1 INTRODUCTION
5.2 CLINICAL
5.2.1 SAMPLE PREPARATION
5.2.2 ASSAY DEVELOPMENT
5.2.3 BIOMARKERS VALIDATION & TESTING
5.2.3.1 Feasibility Studies and choice of assay & biomarker
5.2.3.2 Long lead time required for Biomarker Assay preparation
5.3 BIOINFORMATICS
5.3.1 FUNCTIONAL GENOMICS & PROTEOMICS DRIVE THE DEMAND FOR BIOINFORMATICS

6 BIOMARKERS APPLICATION MARKET
6.1 INTRODUCTION
6.2 DRUG DISCOVERY & DEVELOPMENT
6.2.1 CLINICAL TRIALS <

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018)" Sep 25, 2013. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/Biomarkers-Market-Discovery-Technologies-Proteomics-Genomics-Imaging-Bioinformatics-Validation-Services-Applications-drug-development-personalized-medicine-Diseases-Oncology-Cardiology-Neurology-Global-Trends-Forecasts-2013-2018-2144-404>
  
APA:
MarketsandMarkets. (2013). Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013-2018) Sep 25, 2013. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/Biomarkers-Market-Discovery-Technologies-Proteomics-Genomics-Imaging-Bioinformatics-Validation-Services-Applications-drug-development-personalized-medicine-Diseases-Oncology-Cardiology-Neurology-Global-Trends-Forecasts-2013-2018-2144-404>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.